Gordon McLaren, M.D., is a hematologist and professor at the University of California, Irvine and the Veterans Affairs Long Beach Healthcare System, Long Beach, CA. He has been involved with research on iron metabolism for over 30 years, including investigations of iron absorption in animals, the normal regulation of intestinal iron absorption in humans, and the altered regulation in patients with hemochromatosis. He is Vice-Chair for 2011 and Chair for 2012 of the Scientific Committee on Iron and Heme for the American Society Hematology. He served as the Medical Director for the UC Irvine Field Center of the NIH-funded Hemochromatosis and Iron Overload Screening (HEIRS) Study that enrolled 20,400 participants at the University of California, Irvine. His experience with iron chelation therapies includes participation in the phase I/2, dose-escalation trial of deferasirox (Exjade) that was conducted for the treatment of iron overload in HFE-related hereditary hemochromatosis. For this research, he will assist with design of the animal studies and will serve as Medical Director for the proposed clinical trial to enroll patients, supervise clinical data monitoring, review laboratory test evaluation, conduct safety and efficacy assessment, and interpret results.